University of New South Wales -

For Industry & Investors

Therapeutics

Nucleic acid therapeutic for novel therapeutic target: DNAzyme targeting c-Jun (Dz13)

Professor Levon Khachigian and his team at the Centre for Vascular Research at the University of New South Wales (UNSW) were the first to deliver DNAzymes into an animal model of human disease in 1999 and have defined the field of DNAzyme therapeutics.

The DNAzymes developed at UNSW are:

stable in serum (3'-3'-linked inverted T)
relatively easy and cheap to synthesis
non-toxic in pre-clinical studies.

Dz13 has the potential to treat nodular BCC (70% of cases), thereby avoiding tissue scarring and disfiguration.

More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

Methods and Compositions for Ocular Regeneration

The technology provides an opportunity to develop an early marker diagnostic kit for ocular disease, in addition to a potential novel therapy allowing the regeneration of corneal tissue in situ.

More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

Methods for Producing Secondary Metabolites

This is a unique platform technology that enables the production of valuable secondary metabolites. The platform is based on the cyanobacterium Synechocystis sp. Non ribosomal synthesis allows microorganisms to produce a diverse range of novel compounds including carboxy acids, heterocyclic rings, fatty acids and non-proteinogenic modified amino acids.

Most examples of these compounds are also highly resistant to physical and chemical degradation making them ideal for use as oral therapeutics.

More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

Versatile Container Molecules for a Multitude of Uses

Cucurbiturils (Qs) are a family of rigid, emically and thermally robust container molecules that have many of the advantages but few of the disadvantages associated with cyclodextrins. They provide a unique opportunity in veterinary and human pharmaceuticals to develop new products and design more efficient delivery systems.

More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document

YY1 Gene Therapy for the Prevention of Restenosis

An opportunity exists for a Pharmaceutical or Biotechnology company to work with the University of New South Wales (UNSW)'s Centre for Vascular Research (CVR) to further develop Yin Yang 1 (YY1), a potent inhibitor of vascular smooth muscle cell and tumour cell proliferation.

YY1 is a GLI-Kruppel-type zinc finger nuclear protein. It has therapeutic potential in occlusive vascular disorders and solid tumours.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

For Industry & Investors NSi Technologies Advanced Materials Renewable Energy & Environment ITC - Telecommunications Electronics Mechanical Therapeutics Diagnostics Biotechnology Medical Devices - Instrumentation Miscellaneous Working with NSi Case Studies FAQ Contact Us		For Industry & Investors NSi Technologies Therapeutics Therapeutics Nucleic acid therapeutic for novel therapeutic target: DNAzyme targeting c-Jun (Dz13) Professor Levon Khachigian and his team at the Centre for Vascular Research at the University of New South Wales (UNSW) were the first to deliver DNAzymes into an animal model of human disease in 1999 and have defined the field of DNAzyme therapeutics. The DNAzymes developed at UNSW are: stable in serum (3'-3'-linked inverted T) relatively easy and cheap to synthesis non-toxic in pre-clinical studies. Dz13 has the potential to treat nodular BCC (70% of cases), thereby avoiding tissue scarring and disfiguration. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document Methods and Compositions for Ocular Regeneration The technology provides an opportunity to develop an early marker diagnostic kit for ocular disease, in addition to a potential novel therapy allowing the regeneration of corneal tissue in situ. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document Methods for Producing Secondary Metabolites This is a unique platform technology that enables the production of valuable secondary metabolites. The platform is based on the cyanobacterium Synechocystis sp. Non ribosomal synthesis allows microorganisms to produce a diverse range of novel compounds including carboxy acids, heterocyclic rings, fatty acids and non-proteinogenic modified amino acids. Most examples of these compounds are also highly resistant to physical and chemical degradation making them ideal for use as oral therapeutics. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document Versatile Container Molecules for a Multitude of Uses Cucurbiturils (Qs) are a family of rigid, emically and thermally robust container molecules that have many of the advantages but few of the disadvantages associated with cyclodextrins. They provide a unique opportunity in veterinary and human pharmaceuticals to develop new products and design more efficient delivery systems. More Information and Contact Details: PDF verison of Non-Confidential Disclosure Document YY1 Gene Therapy for the Prevention of Restenosis An opportunity exists for a Pharmaceutical or Biotechnology company to work with the University of New South Wales (UNSW)'s Centre for Vascular Research (CVR) to further develop Yin Yang 1 (YY1), a potent inhibitor of vascular smooth muscle cell and tumour cell proliferation. YY1 is a GLI-Kruppel-type zinc finger nuclear protein. It has therapeutic potential in occlusive vascular disorders and solid tumours. More Information and Contact Details: PDF version of Non-Confidential Disclosure Document
Privacy statement Copyright and Disclaimer Site Map Site Feedback NewSouth Innovations - UNSW Sydney NSW 2052, Australia Telephone: +61 2 9385 5008 Enquiries: info@nsinnovations.com.au AUTHORISED BY Director, Public Affairs and Development. Page last updated: 13-5-2009